Beijing Beilu Pharmaceutical (300016.SZ) obtained the drug registration certificate for Bimatoprost Eye Drops.
Beijing Beilu Pharmaceutical (300016.SZ) announced that the company recently received the Drug Registration Certificate for Bimatoprost Eye Drops approved and issued by the National Medical Products Administration. The originator of Bimatoprost Eye Drops is Allergan of the United States, and the product is used to reduce intraocular pressure in patients with open-angle glaucoma and ocular hypertension. Bimatoprost Eye Drops was approved under Category 4 of chemical drugs and is deemed to have passed the consistency evaluation of the quality and efficacy of generic drugs, further enriching the company's formulation product pipeline and achieving product layout in the ophthalmology field.
Beijing Beilu Pharmaceutical (300016.SZ) announced that the company recently received the Drug Registration Certificate for Bimatoprost Eye Drops approved and issued by the National Medical Products Administration. The originator of Bimatoprost Eye Drops is Allergan, Inc. of the United States, and it is used to reduce intraocular pressure in patients with open-angle glaucoma and ocular hypertension. Bimatoprost Eye Drops was approved under Category 4 of chemical drugs, and is deemed to have passed the consistency evaluation of generic drug quality and efficacy, further enriching the company's formulation product pipeline and achieving product layout in the ophthalmology field.
Related Articles
Ingenic Semiconductor (03223) spent RMB 54.2065 million on September 21 to repurchase 370,000 A shares.
Beijing Yanjing Brewery (000729.SZ): A person acting in concert with the controlling shareholder plans to increase its shareholding in the company by 50 million yuan to 100 million yuan.
SF INTRA-CITY (09699) repurchased 788,200 shares for HK$7.139 million on September 21.
Ingenic Semiconductor (03223) spent RMB 54.2065 million on September 21 to repurchase 370,000 A shares.
Beijing Yanjing Brewery (000729.SZ): A person acting in concert with the controlling shareholder plans to increase its shareholding in the company by 50 million yuan to 100 million yuan.
SF INTRA-CITY (09699) repurchased 788,200 shares for HK$7.139 million on September 21.
RECOMMEND
